Classes
DEA Class; Rx
Common Brand Names; Cleviprex
- Calcium Channel Blockers;
- Calcium Channel Blockers, Dihydropyridine
Description
Intravenous dihydropyridine calcium channel blocker
Used for hypertension when oral therapy is not feasible or desirable
Delivered in a lipid emulsion vehicle
Indications
Indicated for the treatment of hypertension when oral therapy is not feasible or desirable.
Contraindications
Hypersensitivity to drug, soy or egg products
Defective lipid metabolism
Acute pancreatitis if accompanied by hyperlipidemia
Severe aortic stenosis
Adverse Effects
- AFib (21%)
- Nausea (21%)
- Acute renal failure (9%)
- Headache (6%)
- Vomiting (3%)
- Cardiac arrest
- Myocardial infarction
- Increased blood triglycerides
- Ileus
- Nausea
- Hypersensitivity
- Hypotension
- Reflex tachycardia
- Decreased oxygen saturation (possible pulmonary shunting)
Warnings
Use aseptic technique and discard unused product within 12hr of stopper puncture
May produce systemic hypotension and reflex tachycardia; if either occurs, decrease dose of drug; there is limited experience with short-duration therapy with beta-blockers as a treatment for drug-induced tachycardia; beta-blocker use for this purpose not recommended
Drug contains approximately 0.2 g of lipid per mL (2.0 kcal); lipid intake restrictions may be necessary for patients with significant disorders of lipid metabolism; for these patients, a reduction in quantity of concurrently administered lipids may be necessary to compensate for amount of lipid infused as part of drug formulation
Dihydropyridine calcium channel blockers can produce negative inotropic effects and exacerbate heart failure; monitor heart failure patients carefully
Drug is not a beta-blocker, does not reduce heart rate, and gives no protection against effects of abrupt beta-blocker withdrawal; beta-blockers should be withdrawn only after gradual reduction in dose
Patients who receive prolonged infusions and are not transitioned to other antihypertensive therapies should be monitored for possibility of rebound hypertension for at least 8 hr after infusion is stopped
There is no information to guide use of drug in treating hypertension associated with pheochromocytoma
Pregnancy and Lactation
Available data based on post-marketing reports with use in pregnant women are not sufficient to inform a drug-associated risk for major birth defects, miscarriage, or adverse maternal or fetal outcomes; there are risks to mother and fetus associated with poorly controlled hypertension in pregnancy
There are no data on presence of drug in human milk, effects on breastfed infant, or on milk production
Maximum Dosage
32 mg/hour IV (Max: 1,000 mL/24 hours due to lipid load restrictions).
32 mg/hour IV (Max: 1,000 mL/24 hours due to lipid load restrictions).
Safety and efficacy have not been established.
Safety and efficacy have not been established.
Safety and efficacy have not been established.
Safety and efficacy have not been established.
How supplied
Clevidipine
infusion solution
- 0.5mg/mL